Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17913807 | 0.89 | NR1H2 (0.43) | NR1H2HPGDDDB1CRBNMEN1 | |
| SCHEMBL18485336 | 0.89 | NR1H2 (0.43) | NR1H2HPGDDDB1CRBNMEN1 | |
| SCHEMBL894559 | 0.88 | HPGD (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL29745515 | 0.88 | NR1H2 (0.55) | NR1H2HPGDDDB1CRBNMEN1 | |
| SCHEMBL2992998 | 0.88 | NR1H2 (0.55) | NR1H2HPGDDDB1CRBNMEN1 | |
| SCHEMBL23230817 | 0.88 | NR1H2 (0.55) | NR1H2HPGDDDB1CRBNMEN1 | |
| SCHEMBL586312 | 0.88 | HPGD (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL389962 | 0.88 | HPGD (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2990494 | 0.87 | NR1H2 (0.43) | NR1H2HPGDDDB1CRBNMEN1 | |
| SCHEMBL1249710 | 0.86 | MEN1 (0.56) | HPGDMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-28 | — | — | US | disclosed |
| US-20260035363-A1 | COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459933-B2 | Compounds and methods of use thereof as antibacterial agents | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4624465-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-10-01 | — | — | EP | disclosed |
| US-20250263390-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-21 | — | — | US | disclosed |
| US-20250255848-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-14 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4508029-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-02-19 | — | — | EP | disclosed |
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007146758-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1753754-A1 | 3- '4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| US-20060293299-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2006-12-28 | — | — | US | disclosed |
| EP-1636181-A1 | SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005116022-A1 | 3- `4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005000809-A1 | SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | ESRRA, FSHR, GPER1 | NR1H2 33/4885HPGD 1266/4885DDB1 2545/4885 |
| US-20250263390-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | GPER1, ESR2, ESRRA | NR1H2 21/4885HPGD 1532/4885DDB1 1891/4885 |
| US-12459933-B2 | Compounds and methods of use thereof as antibacterial agents | NDUFB7, MRPL21, SQLE | NR1H2 308/4885HPGD 641/4885DDB1 1718/4885 |
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | MRPL21, ARG1, OXA1L | NR1H2 903/4885HPGD 1656/4885DDB1 3754/4885 |
| US-20250255848-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, FSHR, GPER1 | NR1H2 52/4885HPGD 847/4885DDB1 1732/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | NR1H2 2175/4885HPGD 1613/4885DDB1 416/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | NR1H2 2913/4885HPGD 2931/4885DDB1 341/4885 |
| US-20260035363-A1 | COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | CBR3, CBR1, NR3C2 | NR1H2 31/4885HPGD 2663/4885DDB1 3090/4885 |
| US-20060293299-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | CNR1, CNR2, MAG | NR1H2 474/4885HPGD 3845/4885DDB1 3475/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | NR1H2 2311/4885HPGD 2483/4885DDB1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.